EUVIMEDEUVIMED entdecken
Crossref

Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study

Vahid Asghariazar, Mohammad Vakili Ojarood, Mohammad Amin Vatankhah, Reza Panahizadeh, Hamed Mohammadi Haris, Nowruz Najafzadeh, Parya Khakbaz, Narges Soozangar, Farhad Jeddi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-08 · 398 (8) · 10155-10167

DOI: 10.1007/s00210-025-03879-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 15.02.2025. Verfasst von Vahid Asghariazar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran. Hauptthemen laut MEDLINE: Stomach Neoplasms, Wnt-5a Protein, Fluorouracil, Metformin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) is one of the most fatal types of solid neoplasms involving individuals globally due to its chemo-resistant and metastatic nature. 5-Fluorouracil (5-FU) resistance is a complex procedure concerning the prognosis of patients with GC treated with this agent. Metformin has recently been highlighted as a member of anti-diabetic agents for its potential anti-cancer influences. In this study, we investigated the chemo-sensitivity and cell death mechanisms by which metformin moderates its effects by targeting ABCB1 (MDR1), DKK1, WNT5A, and chemo-resistance proteins (P-gp and CD44) on 5-FU-resistant gastric cancer cells. MTT assay exhibited that the combined metformin treatment with 5-FU had a more cytotoxic effect than 5-FU alone. DAPI staining proved that metformin, 5-FU, and co-treatment of them exerted an apoptotic effect on GC cells. Immunocytochemistry illustrated that metformin and its combination with 5-fluorouracil reduced the protein expressions of CD44 and P-gp, compared to the control group. The outcomes of this research displayed that the co-treatment of metformin with 5-FU significantly diminished the expressions of ABCB1, WNT5A, and DKK1 in comparison to the control. The co-treatment of these agents also decreased the expression of WNT5A and ABCB1 compared to 5-FU alone group. Overall, this study's findings demonstrated that co-treating metformin with 5-FU could overcome chemoresistance in GC cells by reducing the expression of WNT5A, MDR1, P-gp, and CD44 levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsWnt-5a ProteinFluorouracilMetforminIntercellular Signaling Peptides and ProteinsAntimetabolites, AntineoplasticHumansDrug Resistance, NeoplasmCell Line, TumorATP Binding Cassette Transporter, Subfamily BDown-RegulationComputational BiologyGene Expression Regulation, NeoplasticApoptosis

Stichwörter der Autor:innen

5-FluorouracilCD44Chemo-resistanceDrug-resistanceMetforminP-gp

Substanzen

Wnt-5a ProteinFluorouracilMetforminWNT5A protein, humanDKK1 protein, humanABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BIntercellular Signaling Peptides and ProteinsAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
  • Deputy of Research & Technology, Ardabil University of Medical Sciences, Ardabil, Iran.
  • Surgery Department, Ardabil University of Medical Sciences, Ardabil, Iran.
  • Department of Radiology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Students Research Committee, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Division of Vascular and Endovascular Surgery, Department of Surgery, Shohada-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Asghariazar, V., Ojarood, M. V., Vatankhah, M. A., Panahizadeh, R., Haris, H. M., Najafzadeh, N., Khakbaz, P., Soozangar, N., & Jeddi, F. (2025). Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study. Naunyn-Schmiedeberg's Archives of Pharmacology, 398(8), 10155-10167. https://doi.org/10.1007/s00210-025-03879-5

Vancouver

Asghariazar V, Ojarood MV, Vatankhah MA, Panahizadeh R, Haris HM, Najafzadeh N, et al. Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(8):10155-10167. doi:10.1007/s00210-025-03879-5

BibTeX
@article{Asghariazar2025,
  author = {Asghariazar, Vahid and Ojarood, Mohammad Vakili and Vatankhah, Mohammad Amin and Panahizadeh, Reza and Haris, Hamed Mohammadi and Najafzadeh, Nowruz and Khakbaz, Parya and Soozangar, Narges and Jeddi, Farhad},
  title = {Metformin reverses 5-FU chemoresistance by downregulating DKK1, WNT5A, and ABCB1 expressions in gastric cancer: An experimental and bioinformatic study},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  volume = {398},
  number = {8},
  pages = {10155--10167},
  doi = {10.1007/s00210-025-03879-5}
}
Kostenlos starten →